TCRR
Price:
$1.48
Market Cap:
$58.11M
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of ren...[Read more]
Industry
Biotechnology
IPO Date
2019-02-14
Stock Exchange
NASDAQ
Ticker
TCRR
According to TCR2 Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -71.90%. This represents a change of 156.32% compared to the average of -28.05% of the last 4 quarters.
The mean historical ROE of TCR2 Therapeutics Inc. over the last ten years is -5.70%. The current -71.90% ROE has changed 1.16% with respect to the historical average. Over the past ten years (40 quarters), TCRR's ROE was at its highest in in the December 2017 quarter at 15.24%. The ROE was at its lowest in in the December 2022 quarter at -42.95%.
Average
-5.70%
Median
-28.38%
Minimum
-107.78%
Maximum
83.43%
Discovering the peaks and valleys of TCR2 Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 203.97%
Maximum Annual ROE = 83.43%
Minimum Annual Increase = -204.83%
Minimum Annual ROE = -107.78%
Year | ROE | Change |
---|---|---|
2022 | -107.78% | 203.97% |
2021 | -35.46% | 24.96% |
2020 | -28.38% | -4.35% |
2019 | -29.67% | -204.83% |
2018 | 28.30% | -43.00% |
2017 | 49.65% | -40.49% |
The current ROE of TCR2 Therapeutics Inc. (TCRR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-57.21%
5-year avg
-34.60%
10-year avg
-5.70%
TCR2 Therapeutics Inc.’s ROE is greater than Affimed N.V. (-193.85%), greater than Pieris Pharmaceuticals, Inc. (-76.24%), less than ADC Therapeutics SA (131.30%), less than Agenus Inc. (131.89%), greater than Revolution Medicines, Inc. (-33.67%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Atreca, Inc. (-199.88%), greater than Passage Bio, Inc. (-72.53%), greater than Harpoon Therapeutics, Inc. (-19.66%), greater than Alector, Inc. (-108.77%), greater than Homology Medicines, Inc. (-100.91%), greater than Stoke Therapeutics, Inc. (-54.45%),
Company | ROE | Market cap |
---|---|---|
-193.85% | $18.12M | |
-76.24% | $17.96M | |
131.30% | $192.41M | |
131.89% | $63.81M | |
-33.67% | $8.01B | |
-68.08% | $123.92M | |
-199.88% | $3.57M | |
-72.53% | $40.03M | |
-19.66% | $865.08M | |
-108.77% | $188.03M | |
-100.91% | $3.02M | |
-54.45% | $614.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TCR2 Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TCR2 Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is TCR2 Therapeutics Inc.'s ROE?
How is the ROE calculated for TCR2 Therapeutics Inc. (TCRR)?
What is the highest ROE for TCR2 Therapeutics Inc. (TCRR)?
What is the 3-year average ROE for TCR2 Therapeutics Inc. (TCRR)?
What is the 5-year average ROE for TCR2 Therapeutics Inc. (TCRR)?
How does the current ROE for TCR2 Therapeutics Inc. (TCRR) compare to its historical average?